NCT06278506Recruiting
Resection or Ablation of Small Kidney Tumors
Resection or Ablative Treatment of Small Renal Tumors, a Multicenter Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 26 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Ablative treatments are believed to have a lower rate of complications, shorter hospital stays, and fewer interventions with benign PAD compared to partial nephrectomies in small kidney cancer lesions. The purpose of the study is to compare complications, the frequency of residual tumors, impact on kidney function, differences in quality of life, and health economic factors in a randomised study. We will also compare the oncological outcomes, including survival and recurrence of kidney cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 30 Jan 2024
- Start date
- 31 Jan 2024
- Primary completion date
- Dec 2027
- Lead sponsor
- Karolinska University Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT06278506
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 31 Jan 2024 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other metastasized cancer in the last 5 years
Other
- Radiological signs of metastasis
- Synchronous kidney tumors
- ISUP grade IV or sarcomatoid growth in the biopsy
- Patient unable to make an informed decision to participate in the study
Who the study is looking for
- Age 18 - 99 years
- Patient suitable based on clinical status for both ablative treatment and surgery
- Primary kidney tumor
- Tumor size ≤ 3 cm
- Clinical stage of the tumor T1a (no macroscopic vascular or extrarenal invasion)
- Tumor location suitable for both ablative treatment and resection
- Absence of radiological signs of metastasis
- Biopsy with malignant pathological analysis (PAD)
- ISUP grade I-III"
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska University Hospital Coordinator of this site? Confirm its status | Stockholm | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.